Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2019 / N 3

Современные представления о роли блокаторов кальциевых каналов в лечении стабильной ишемической болезни сердца и артериальной гипертонии в свете новых европейских рекомендаций
М.М. Руда, Ю.А. Карпов

References

1. Karpov YuA, Kukharchuk VV, Lyakishev AA, Lupanov VP, Panchenko EP, Komarov AL, Shiryaev AA, Samko AN, Soboleva GN, Sorokin EV. Diagnosis and treatment of chronic coronary heart disease. Practical guidelines. Kardiologicheskij Vestnik 2015;10(3):3-33 (In Russian).
2. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal 2019 Aug 31. pii: ehz425. doi: 10.1093/eurheartj/ehz425. [Epub ahead of print].
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018 Sep;39(33):3021-104.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2007 Jun;25(6):1105-87.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. The Lancet 1998 Jun;351(9118):1755-62.
6. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. Journal of Hypertension 2005 Dec;23(12):2157-72.
7. Kjeldsen SE, Hedner H, Jamerson K, Julius S, Haley WE, Zabalgoitia M, Butt AR, Rahman SN, Hansson L. Hypertension Optimal Treatment (HOT) Study. Home blood pressure in treated hypertensive subjects. Hypertension (Dallas, Tex.: 1979) 1998 Apr;31(4):1014-20.
8. Herlitz H, Harris K, Risler T, Boner G, Bernheim J, Chanard J, Aurell M. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrology, Dialysis, Transplantation 2001 Nov;16(11):2158-65.
9. Sidorenko BA, Preobrazhenskiy DV. Calcium channel blockers in cardiological practice. Moscow: Precid; 1997. 122 p. (In Russian).
10. Belousov YuB, Moiseyev VC, Lepakhin VK. Clinical pharmacology and pharmacotherapy. A guide for physicians. Moscow: Universum Publishing; 2000: 97-110, 150-2 (In Russian).
11. Belousov YuB, Leonova MV. Prolonged-acting Calcium channel blockers and cardiovascular morbidity: new evidence-based medicine data. Kardiologiia 2001;41(4):87-93 (In Russian).
12. Wong ND, Teng W, Abrahamson D, Willner R, Henein N, Franklin SS, Kashyap ML, Rosenzweig B, Kukes G, Detrano RC. Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS). The American Journal of Cardiology 1995 Dec;76(17):1239-42.
13. Podjarny E, Korzets Z, Bernheim J. Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office and ambulatory blood pressure monitoring. Journal of Human Hypertension 1996 Sep;10(Suppl 3):S153-6.
14. Antonicelli R, Omboni S, Giovanni DC, Ansuini R, Mori A, Gesuita R, Parati G, Paciaroni E. Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Drugs & Aging 2002;19(7):541-51.
15. Manzo BA, Matalka MS, Ravnan SL. Evaluation of a therapeutic conversion from amlodipine to felodipine. Pharmacotherapy 2003 Nov;23(11):1508-12.
16. Kukes VG, Ostroumova OD, Starodubtsev AK. Calcium channel blockers (CCB): modern aspects of application in cardiology. Consilium Medicum 2006;8(11):113-7 (In Russian).
17. Lehrl S, Grossel E, Eicke C. Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study. Deutsche Medizinische Wochenschrift 2000 Nov;125(45):1350-5.
18. Meyer FP. Felodipine in hypertensive patients with mild encephalopathies. Deutsche Medizinische Wochenschrift 2001 Jun;126(19):577-8.
19. Ito Y, Araki N. Calcium antagonists: current and future applications based on new evidence. Neuroprotective effect of calcium antagonists. Clinical Calcium 2010 Jan;20(1):83-8.
20. Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Girerd X, Singh GP, Rehn L, Morgan TO. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. International Journal of Clinical Practice 1998 Sep;52(6):381-6.
21. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension (Dallas, Tex.: 1979) 2008 Mar;51(3):742-8.
22. Matsubara BB, Franco M, Janicki JS, Matsubara LS. Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. Brazilian Journal of Medical and Biological Research 2010 May;43:506-14.
23. Bicchi M, Vedovini G, Cappelli R, Arrigucci S, Righi GA, Forconi S. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology 1998 May;49(5):373-80.
24. Wu Y, Xu M, Wang H, Xu X, Zhao S, Zhang M, Jin H, Yan J, Wang B, Gong J, Lu X, Peng J, Dai Q. Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial. Current Medical Research & Opinion 2015 Jan;31(1):171-6.
25. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013 Jul;31(7):1281-357.
26. Clinical guidelines. Diagnostics and treatment of arterial hypertension. Authors (working group preparing practice guidelines): Chazova IE, Oshepkova EV, Zhernakova YuV. Kardiologicheskij Vestnik 2015;10(1):3-30 (In Russian).
27. Corradi L, Colombo G, Ravera E, Lotto A. Clinical interest of once-daily felodipine extended-release in patients with mixed and exertional angina. Results of a double-blind crossover study versus amlodipine. Clinical Drug Investigation 1995 Jun;9(6):324-33.
28. Ageyev FT, Fofanova TV, Deyev AD. Felodipine in outpatient practice: evaluation of clinical efficacy and adherence to treatment in patients with hypertension. Kardiologiia 2009;49(1):30-3 (In Russian).
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]